A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo

The American Journal of Cardiology

Volumn 59, Issue 10, 1987, Pages

  Villamil, Alberto S ^a,b   Cairns, Victoria ^a,b   Witte, Peter U ^a,b   Bertolasi, Carlos A ^a,b  

^a HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RAMIPRIL;

ADVERSE DRUG REACTION; BULIMIA; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DIGESTIVE SYSTEM; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DRUG TOLERANCE; DUODENUM ULCER; DYSPEPSIA; ENERGY LOSS; ESSENTIAL HYPERTENSION; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; INSOMNIA; INTOXICATION; MAJOR CLINICAL STUDY; MUSCLE; MUSCLE SPASM; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; SMALL INTESTINE; THERAPY;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BICYCLO COMPOUNDS; BLOOD PRESSURE; BRIDGED COMPOUNDS; CLINICAL TRIALS; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYPERTENSION; MALE; RAMIPRIL; RANDOM ALLOCATION;

EID: 0023235423     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(87)90064-6     Document Type: Article

References (11)

1. Pharmacological properties of the new orally active converting enzyme inhibitor HOE 498
2. Cardiovascular and antihypertensive activities of the novel nonsulphhydryl converting enzyme inhibitor HOE 498
3. Pharmacodynamics of a new orally active long acting angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects
4. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor in hypertensive patients
5. Effects of the new oral angiotensin converting enzyme inhibitor HOE 498 in essential hypertension
6. Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension
7. HOE 498—a new highly effective angiotensin I converting enzyme inhibitor
8. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor HOE 498 in healthy volunteers
9. Captopril: evaluation of low doses, twice-daily doses and the addition of diuretic for the treatment of mild to moderate hypertension
10. A controlled multiclinic study to compare the antihypertensive effects of MK-421 hydrochlorothiazide and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension
11. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects